ACP-105 SARM – 20MG/ML – 60ML BOTTLE

ACP-105 is a nonsteroidal selective androgen receptor modulator (SARM) that was originally developed in 2008 by the biopharmaceutical company ACADIA Pharmaceuticals. Like most SARMs, ACP-105 is capable of binding to androgen receptors in a manner similar to testosterone which ultimately results in enhanced anabolic activity in bones and muscles.

In addition to its anabolic effects, ACP-105 has also been shown to improve various aspects of cognition. Decreases in reproductive hormones like testosterone and estrogen lead to an increased risk for Alzheimer’s Disease and age-related cognitive decline. Current research has reported that ACP-105 can potentially combat deficits in cognitive functioning since the SARM acts a selective agonist to the androgen receptors.